Vertex Pharmaceuticals Inc (MIL:1VRTX) Stock Price, Trades & News

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	3.65
Equity-to-Asset	0.73
Debt-to-Equity	0.1
Debt-to-EBITDA	0.38
Interest Coverage	452.63
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	13.52	Distress Grey Safe
Beneish M-Score	-2.37	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	10.5
	3-Year EBITDA Growth Rate	3.3
	3-Year EPS without NRI Growth Rate	7.3
	3-Year FCF Growth Rate	-6.5
	3-Year Book Growth Rate	10.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	10.47
	Future 3-5Y Total Revenue Growth Rate Estimate	9.75

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	78.99
	9-Day RSI	78.58
	14-Day RSI	76.16
	3-1 Month Momentum %	-4.09
	6-1 Month Momentum %	-5.42
	12-1 Month Momentum %	-5.4

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.02
	Quick Ratio	2.57
	Cash Ratio	1.87
	Days Inventory	344.76
	Days Sales Outstanding	57.92
	Days Payable	98.08

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.4
	Shareholder Yield %	1.43

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	86.24
	Operating Margin %	38.16
	Net Margin %	35.51
	EBITDA Margin %	43.21
	FCF Margin %	30.41
	OCF Margin %	34.75
	ROE %	24.37
	ROA %	17.51
	ROIC %	26.68
	3-Year ROIIC %	5.25
	ROC (Joel Greenblatt) %	157.07
	ROCE %	24.39
	Years of Profitability over Past 10-Year	8
	Moat Score	8
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	31.32
	Forward PE Ratio	26.7
	PE Ratio without NRI	28.06
	Shiller PE Ratio	59.83
	Price-to-Owner-Earnings	42.08
	PS Ratio	11.12
	PB Ratio	6.93
	Price-to-Tangible-Book	7.52
	Price-to-Free-Cash-Flow	36.62
	Price-to-Operating-Cash-Flow	32.04
	EV-to-EBIT	27.04
	EV-to-Forward-EBIT	24.19
	EV-to-EBITDA	25.92
	EV-to-Forward-EBITDA	22.99
	EV-to-Revenue	11.2
	EV-to-Forward-Revenue	9.88
	EV-to-FCF	34.7
	Price-to-GF-Value	1.05
	Price-to-Projected-FCF	2.79
	Price-to-Median-PS-Value	0.97
	Price-to-Graham-Number	3.06
	Price-to-Net-Current-Asset-Value	29.12
	Price-to-Net-Cash	1068.29
	Earnings Yield (Greenblatt) %	3.7
	FCF Yield %	2.61
	Forward Rate of Return (Yacktman) %	-9.84

Financials (Next Earnings Date:2026-08-04 Est.)

Annual Quarterly TTM

MIL:1VRTX's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Vertex Pharmaceuticals Inc Executives

Details

GF Value™: €417.72

MIL:1VRTX

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 1VRTX. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	10,499.416
	EPS (TTM) (€)	14.485
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	28.05
	14-Day RSI	76.16
	14-Day ATR (€)	5.653836
	20-Day SMA (€)	406.3475
	12-1 Month Momentum %	-5.4
	52-Week Range (€)	316 - 438.25
	Shares Outstanding (Mil)	253.81

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Vertex Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Vertex Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-03 16:30	In 124 days
Third quarter earnings results for 2026	2026-11-03	In 123 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 33 days
Second quarter earnings results for 2026	2026-08-04	In 32 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-10 11:20	387.10 (+0.00%)
Bernstein’s 42nd Annual Strategic Decisions Conference (SDC)	2026-05-29 09:00	378.00 (+0.00%)
RBC Capital Markets Global Healthcare Conference	2026-05-19 14:35	379.85 (+0.00%)
General meeting for 2026	2026-05-13 09:00	363.60 (+0.00%)
First quarter earnings conference call for 2026	2026-05-04 16:30	374.65 (+0.00%)
First quarter earnings results for 2026	2026-05-04	374.65 (+0.00%)

Show

Entries

Vertex Pharmaceuticals Inc Frequently Asked Questions

What is Vertex Pharmaceuticals Inc(MIL:1VRTX)'s stock price today?

The current price of MIL:1VRTX is €438.00. The 52 week high of MIL:1VRTX is €438.25 and 52 week low is €316.00.

When is next earnings date of Vertex Pharmaceuticals Inc(MIL:1VRTX)?

The next earnings date of Vertex Pharmaceuticals Inc(MIL:1VRTX) is 2026-08-04 Est..

Does Vertex Pharmaceuticals Inc(MIL:1VRTX) pay dividends? If so, how much?

Vertex Pharmaceuticals Inc(MIL:1VRTX) does not pay dividend.

Press Release

	Subject	Date
	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	2026-07-01
	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5--11, at the European Hematology Association Congress and Announces Additional Global Regulatory Su	2026-06-11
	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	2026-06-05
	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	2026-06-03
	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	2026-06-01
	Vertex to Announce First Quarter 2026 Financial Results on May 4th	2026-04-06
	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States	2026-04-01
	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy	2026-03-09
	Vertex to Participate in Upcoming March Investor Conferences	2026-03-05
	Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures	2026-03-05

10/Page

Articles on Vertex Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.